China approves favipiravir for influenza (with hopes to treat Covid-19)
China’s NMPA gave the nod to Hisun Pharma’s antiviral drug favipiravir for novel or recurring strains of influenza virus. The drug has been on the Japanese market since 2014 as an anti-influenza medication called Avigan. In 2016, Toyama Chemical agreed to license it out to Hisun Pharma so the latter could develop it in China.
But like so many other pharma stories in China these days, this one has a tie-in to Covid-19. In a statement, the NMPA said the approval was “in response to the novel coronavirus pneumonia epidemic,” after authorities said the drug may have potential to help treat patients with Covid-19.
Regulators also authorized Hisun, based in Zhejiang, to run clinical trials to further test its efficacy against the novel coronavirus that causes the disease.
But like so many other pharma stories in China these days, this one has a tie-in to Covid-19. In a statement, the NMPA said the approval was “in response to the novel coronavirus pneumonia epidemic,” after authorities said the drug may have potential to help treat patients with Covid-19.
Regulators also authorized Hisun, based in Zhejiang, to run clinical trials to further test its efficacy against the novel coronavirus that causes the disease.
.png)
No hay comentarios:
Publicar un comentario